MetaCap

Amgen Inc. (AMGN)

NASDAQ: AMGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

413.08+10.48 (+2.60%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

AMGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$223.32B
P/E (TTM)
25.66
Forward P/E
16.88
EPS (TTM)
$16.10
Dividend yield
2.37% ($9.80)
Ex-dividend date
Aug 21, 2026
52-week range
288.00 – 447.03
Day range
401.85 – 415.79
Volume / Avg
2.22M / 2.72M
Beta
—
Shares outstanding
540.63M
Next earnings
Nov 3, 2026

52-week range

$288.00$447.03

AMGN stock today

Amgen (AMGN) closed at $413.08 on Oct 7, up 2.60% (+$10.48), versus the S&P 500's 0.22% decline. Shares are 7.6% below their 52-week high of $447.03, set on Aug 25, 2026 and 43.4% above the 52-week low of $288.00, in the middle of the past year's range. AMGN is up 26.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 39.6%.

At 25.7x trailing earnings, Amgen trades in line with the peer-group median of 28.2x. Its forward P/E of 16.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Amgen's next earnings report is expected on Nov 3, 2026. Amgen pays an annual dividend of $9.80 per share, a 2.37% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Amgen

Company profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Robert A. Bradway
Headquarters
Thousand Oaks, CA
Employees
31,500
IPO year
1983
Website
amgen.com

Financial highlights

Full financials

In fiscal 2025, Amgen generated $36.75 billion in revenue, up 10.0% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $7.71 billion (+88.5% year over year), for a net margin of 21.0% versus a median of 23.8% in the prior 5 years. Gross margin was 67.2% (up from 61.5%) and operating margin 24.7%.

Amgen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$36.75B$33.42B$28.19B$26.32B$25.98B
Growth+9.95%+18.57%+7.09%+1.32%+2.18%
Net income$7.71B$4.09B$6.72B$6.55B$5.89B
EPS (diluted)$14.23$7.56$12.49$12.11$10.28

Analyst forecast

Forecast

Consensus (34 analysts)

hold

Avg. price target

$391.46-5.23%

  • Strong buy 4
  • Buy 8
  • Hold 17
  • Sell 3
  • Strong sell 2

Target range

Low $225.00High $500.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 3, 2026
EPS estimate
$5.69
Last reported (Q2 2026)
Aug 5, 2026
EPS actual vs est.
$4.37 vs —

Dividends

Dividend history
Annual dividend
$9.80
Dividend yield
2.37%
Last payment
$2.52
Ex-dividend date
Aug 21, 2026

AMGN news

All AMGN news

Amgen peers

Health Care sector
AMGN peer companies
CompanyPrice% ChgMarket capCompare
GILDGilead Sciences Inc.146.85+1.82%$182.09Bvs AMGN
MRNAModerna Inc.196.48+4.81%$78.44Bvs AMGN
ARGXargenx SE ADR928.44-0.22%$57.74Bvs AMGN
RVMDRevolution Medicines Inc.200.87+0.50%$43.05Bvs AMGN
BIIBBiogen Inc.222.15-0.33%$32.82Bvs AMGN
BNTXBioNTech SE ADR95.25-0.50%$23.93Bvs AMGN
NBIXNeurocrine Biosciences Inc.143.47-1.40%$14.58Bvs AMGN
EXELExelixis Inc.58.44+0.19%$14.48Bvs AMGN

Indexes, lists and sector

Index membership

Appears in lists

Amgen stock FAQ

What is Amgen's stock price today?

AMGN last traded at $413.08 as of Oct 7, 4:00 PM EDT, up 2.60% on the day. Prices are delayed at least 15 minutes.

Does Amgen pay a dividend?

Yes. Amgen pays $9.80 per share annually, a 2.37% yield. The most recent dividend of $2.52 had an ex-dividend date of Aug 21, 2026.

When is Amgen's next earnings date?

Amgen is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $5.69.

What is AMGN's P/E ratio?

AMGN trades at a trailing P/E ratio of 25.66 and a forward P/E of 16.88, compared with a median of 28.2 for its closest peers.

Is Amgen in the S&P 500?

Yes. Amgen (AMGN) is a constituent of the S&P 500 index.

Who is Amgen's CEO?

Mr. Robert A. Bradway is the chief executive officer of Amgen Inc., which has about 31,500 employees.

Has AMGN ever split its stock?

Yes. The most recent AMGN stock split was a 2-for-1 split on Nov 22, 1999, one of 5 splits on record.

Compare AMGN